Z92.22Personal history of monoclonal drug therapy

Z92.22 is the ICD-10-CM diagnosis code for personal history of monoclonal drug therapy. It belongs to category Z92 (personal history of medical treatment), block Z77-Z99 (persons with potential health hazards related to family and personal history and certain conditions influencing health status) and chapter 21 (factors influencing health status and contact with health services). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within Z92.2 (personal history of drug therapy), Z92.22 is specifically for personal history of monoclonal drug therapy. Related codes cover antineoplastic chemotherapy (Z92.21), estrogen therapy (Z92.23), steroid therapy (Z92.24), immunosuppression therapy (Z92.25), immune checkpoint inhibitor therapy (Z92.26) and other drug therapy (Z92.29).

The conditions in its Excludes2 note aren't part of Z92.22, but may be coded alongside it if the patient has both: personal history of immune checkpoint inhibitor therapy (Z92.26).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 949 (Aftercare with CC/MCC, relative weight 1.123) and DRG 950 (Aftercare without CC/MCC, relative weight 0.7664), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as V87.42 (personal history of monoclonal drug therapy).